TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial

Phase 2

Not yet recruiting

• Conditions: Nasopharyngeal Carcinoma (NPC)
• Interventions: Drug: Toripalimab; Drug: Capecitabine; Procedure: salvage surgery

• Registration Number: NCT06987123
• Lead Sponsor: Sun Yat-sen University

Brief Summary

Regarding the application value of capecitabine metronome chemotherapy's regulatory effect on the immune microenvironment in nasopharyngeal carcinoma, many studies in recent years have confirmed that metronome chemotherapy and immunotherapy are safe and effective in resectable recurrent nasopharyngeal carcinoma. Therefore, the investigators plan to conduct a "single-arm clinical study on adjuvant therapy of toripalimab combined with capecitabine after Surgery for locally recurrent resectable nasopharyngeal carcinoma" to explore the efficacy and safety of toripalimab combined with capecitabine as adjuvant therapy after salvage surgery for resectable recurrent nasopharyngeal carcinoma. If this study is confirmed, it is expected to provide a new treatment model for patients with resectable recurrent nasopharyngeal carcinoma.

Detailed Description

Regarding the application value of capecitabine metronome chemotherapy's regulatory effect on the immune microenvironment in nasopharyngeal carcinoma, many studies in recent years have confirmed that metronome chemotherapy and immunotherapy are safe and effective in resectable recurrent nasopharyngeal carcinoma. Therefore, the investigators plan to conduct a "single-arm clinical study on adjuvant therapy of toripalimab combined with capecitabine after Surgery for locally recurrent resectable nasopharyngeal carcinoma" to explore the efficacy and safety of toripalimab combined with capecitabine as adjuvant therapy after salvage surgery for resectable recurrent nasopharyngeal carcinoma. If this study is confirmed, it is expected to provide a new treatment model for patients with resectable recurrent nasopharyngeal carcinoma.The diagnosis was pathologically confirmed as locally recurrent nasopharyngeal carcinoma. According to the TNM staging of recurrent nasopharyngeal carcinoma (AJCC, 8th Edition, 2018), resectable nasopharyngeal diseases: rT1 (the tumor was confined to the nasopharynx, oropharynx and/or nasal cavity, and did not involve the parapharynx); rT2 (The tumor is confined to the superficial septum beside the pharynx, more than 0.5 cm away from the internal carotid artery) and rT3 (the tumor is confined to the basal wall of the sphenoid sinus, more than 0.5 cm away from the internal carotid artery and the cavernous sinus); Resectable recurrent regional lymph nodes (rN1-3), without involvement of the anterior vertebral fascia, cervical vertebrae or common carotid artery/internal carotid artery.

Study Timeline

• Status Verified: 2025-05
• Study First Submitted: 2025-05-15
• Study First Submitted QC: 2025-05-15
• Last Update Submitted: 2025-05-15
• Study Start: 2025-05-18
• Study First Posted: 2025-05-23
• Last Update Posted: 2025-05-23
• Primary Completion: 2029-06-01
• Study Completion: 2029-06-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

• Pathologically confirmed as locally recurrent nasopharyngeal carcinoma, according to the TNM staging of recurrent nasopharyngeal carcinoma (AJCC, 8th Edition, 2018), resectable nasopharyngeal diseases: rT1 (the tumor is confined to the nasopharynx, oropharynx and/or nasal cavity, and does not involve the parapharynx); rT2 (The tumor is confined to the superficial septum beside the pharynx, more than 0.5 cm away from the internal carotid artery) and rT3 (the tumor is confined to the basal wall of the sphenoid sinus, more than 0.5 cm away from the internal carotid artery and the cavernous sinus); Resectable recurrent regional lymph nodes (rN1-3), without involvement of the anterior vertebral fascia, cervical vertebrae or common carotid artery/internal carotid artery.
• It has been more than 6 months since the last radiotherapy
• Age: 18-70 years old, gender not limited;
• ECOG score: 0-1 point;
• The functions of the major organs are normal, that is, the following standards are met; (1) The blood routine examination standards must meet (no blood transfusion or blood products within 14 days) : a. HB≥90 g/L; b. ANC≥1.5×109/L; c. PLT≥80×109/L; (2) Biochemical tests must meet the following standards: a. TBIL<1.5× upper normal limit (ULN); b. ALT and AST<2.5×ULN; c. Serum Cr≤1.5×ULN or endogenous creatinine clearance rate > 45 ml/min;
• Women of childbearing age should agree to use contraceptive measures during the study period and within 6 months after the end of the study (e.g Intrauterine devices, contraceptive pills or condoms; The serum or urine pregnancy test must be negative within 7 days before enrollment in the study, and the patient must be a non-lactating patient. Male patients who should agree that contraceptive measures must be adopted during the study period and within 6 months after the end of the study period;
• Sign the informed consent form and voluntarily participate in the clinical trial research project.

Exclusion Criteria

• The tumor broke through the dura mater at the base of the skull and severely involved the brain parenchyma, with distant metastasis and obvious complications, and the patient could not be under general anesthesia.
• Patients with tumor recurrence or residual after re-radiotherapy.
• The patient has any active autoimmune diseases or a history of autoimmune diseases (such as the following, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism; Vitiligo Asthma that requires medical intervention with bronchodilators;
• Patients who are currently undergoing immunosuppressive therapy with immunosuppressants or systemic hormones to achieve the purpose of immunosuppression (dose >10mg/ day prednisone or other therapeutic hormones) and are still continuing to use them within 2 weeks before enrollment;
• Have received immunotherapy within the past six months;
• Patients with any severe and/or uncontrollable diseases, including: those with unsatisfactory blood pressure control (systolic) Patients with blood pressure >=160mmHg or diastolic blood pressure >=100 mmHg; Suffering from grade II or above myocardial ischemia or myocardial infarction, arrhythmia (including QT interval >=480ms), and grade II cardiac insufficiency; Active or uncontrolled severe infection; Liver diseases such as decompensated liver disease, active hepatitis B (HBV-DNA>=104 copy number /ml or 2000IU/ml) or hepatitis C (positive hepatitis C antibody and HCV-RNA higher than the detection limit of the analytical method);
• Pregnant or lactating women; Patients with other malignant tumors within 8.5 years (except for cured basal cell carcinoma of the skin and cervical carcinoma in situ);
• Those with a history of abuse of psychotropic drugs and who are unable to quit or those with mental disorders;
• Patients who have participated in clinical trials of other similar drugs within three months;
• According to the researcher's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study;
• Those that the researchers consider unsuitable for inclusion.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Experimental group	Toripalimab	Toripalimab in combination with capecitabine as adjuvant therapy after surgery for locally recurrent resectable nasopharyngeal carcinoma
Experimental group	Capecitabine	Toripalimab in combination with capecitabine as adjuvant therapy after surgery for locally recurrent resectable nasopharyngeal carcinoma
Experimental group	salvage surgery	Toripalimab in combination with capecitabine as adjuvant therapy after surgery for locally recurrent resectable nasopharyngeal carcinoma

Primary Outcome Measures

Name	Time	Method
2-year progression-free survival	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.	2-year progression-free survival